What concerns do patients bring up and how might they be addressed?

Many patients find the infusion process onerous as well, since they must be in a location where there is immediate access to medications to treat a severe infusion reaction (eg, anaphylaxis) and must be under observation for an hour following the infusion to monitor for adverse effects.

Nevertheless, these agents have shown a high level of efficacy in treating COVID-19 and these practical concerns should not deter clinicians from referring patients for treatment.

I encourage clinicians to provide patients with reliable resources for education about antibody therapy (Table 1). There are many misconceptions in this day and age about all aspects of COVID-19 that accurate information is essential and will also encourage eligible patients to be treated with antibody therapy.


Continue Reading

Table 1

Patient Education Websites

National Infusion Center Association
https://infusioncenter.org/infusion-patients-covid-antibody-treatment-resources/

US Department of Health and Human Services
https://www.phe.gov/emergency/events/COVID19/therapeutics/Pages/patients.aspx

References

  1. Yang X, Liu Y, Liu Y, Yang Q, Wu X, Huang X, Liu H, Cai W, Ma G. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. Expert Rev Clin Pharmacol. Published online August 4, 2020. doi.org/10.1080/17512433.2020.1805315.
  2. US Department of Health and Human Services. Monoclonal antibodies for high-risk COVID-19 patients. Available at: https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients?gclid=Cj0KCQjwp86EBhD7ARIsAFkgakgUA8WIBY5QrBB4OmlGl1dPvhwPRsUIgp3g9T9P8OVw7c_x2Kv4kT8aAvv0EALw_wcB. Accessed: April 13, 2021.
  3. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Chi-Chung Cheng V, et al. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. April 14, 2021. Available at: https://www.idsociety.org/COVID19guidelines Accessed: April 20, 2021.
  4. Infectious Disease Society of America. Monoclonal Antibodies. Available at: https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-interventions/monoclonal-antibodies/. Accessed: April 30, 2021.
  5. National Institutes of Health (NIH). Anti-SARS-CoV-2 Monoclonal Antibodies. Available at: https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/. Accessed: April 21, 2021.
  6. Centers for Disease Control and Prevention (CDC). Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Paged reviewed May 14, 2021. Available at: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html Accessed: May 16, 2021.
  7. US Department of Health and Human Services. Biden Administration to Invest $150 Million to Expand Access to COVID-19 Treatments in Underserved Communities March 17, 2021. Available at: https://www.hhs.gov/about/news/2021/03/17/biden-administration-to-invest-150-million-to-expand-access-to-covid-19-treatments-in-underserved-communities.html. Accessed: April 18, 2021.